Adjuvant trastuzumab therapy is recommended for 12 months. Trastuzumab therapy has great potential but is associated with high cost and cardiac toxicity, demonstrated below:
- In the United States (US), the cost is approximately $100,000
- 5% to 15% of patients develop cardiac dysfunction
- 1% to 4% develop significant cardiac events while taking trastuzumab
